We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
Read MoreHide Full Article
Zogenix, Inc. announced that the FDA has approved Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with DravetSyndrome in patients 2 years of age or older.
The FDA’s approval was based on data from two placebo-controlled phase III studies and safety data from an extension study. The data showed that when Fintepla was added to existing treatments, the drug significantly reduced monthly convulsive seizure frequency compared to placebo in patients whose seizures were not adequately controlled byantiepileptic drugs. Further, most study patients responded to the treatment with Fintepla within three to four weeks and the effects remained consistent over the treatment period.
Fintepla will be launched through a restricted distribution program, called the Fintepla Risk Evaluation and Mitigation Strategy (REMS) Program. The drug is expected to be available through Zogenix's specialty pharmacy partner by the end of July.
Approval of the drug will be a boost the company’s sales.
Shares of the company have slumped 46.1% year to date compared with the industry’s decline of 4.7%.
Dravet syndrome is a rare childhood-onset epilepsy, marked by frequent and severe treatment-resistant seizures as well as significant developmental and motor impairments, and an increased risk of sudden unexpected death.
We remind investors that GW Pharmaceuticals PLC’s Epidiolex oral solution was approved by the FDA in 2018 for the treatment of Dravet syndrome in patients 2years of age or older.
Amneal’s earnings per share estimates have increased from 49 cents to 57 cents and from 63 cents to 67 cents for 2020 and 2021, respectively, in the past 60 days.
MEI Pharma’sloss per share estimates have narrowed from 58 cents to 14 cents for 2020 and from 53 cents to 39 centsfor 2021 over the past 60 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Zogenix Gets FDA Nod for Dravet Syndrome Seizure Treatment
Zogenix, Inc. announced that the FDA has approved Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with DravetSyndrome in patients 2 years of age or older.
The FDA’s approval was based on data from two placebo-controlled phase III studies and safety data from an extension study. The data showed that when Fintepla was added to existing treatments, the drug significantly reduced monthly convulsive seizure frequency compared to placebo in patients whose seizures were not adequately controlled byantiepileptic drugs. Further, most study patients responded to the treatment with Fintepla within three to four weeks and the effects remained consistent over the treatment period.
Fintepla will be launched through a restricted distribution program, called the Fintepla Risk Evaluation and Mitigation Strategy (REMS) Program. The drug is expected to be available through Zogenix's specialty pharmacy partner by the end of July.
Approval of the drug will be a boost the company’s sales.
Shares of the company have slumped 46.1% year to date compared with the industry’s decline of 4.7%.
Dravet syndrome is a rare childhood-onset epilepsy, marked by frequent and severe treatment-resistant seizures as well as significant developmental and motor impairments, and an increased risk of sudden unexpected death.
We remind investors that GW Pharmaceuticals PLC’s Epidiolex oral solution was approved by the FDA in 2018 for the treatment of Dravet syndrome in patients 2years of age or older.
Zogenix, Inc. Price
Zogenix, Inc. price | Zogenix, Inc. Quote
Zacks Rank & Stocks to Consider
Zogenix currently carries a Zacks Rank #2 (Buy).
Some better-ranked stocks from the same space are Amneal Pharmaceuticals Inc. (AMRX - Free Report) and MEI PharmaInc. (MEIP - Free Report) , each carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Amneal’s earnings per share estimates have increased from 49 cents to 57 cents and from 63 cents to 67 cents for 2020 and 2021, respectively, in the past 60 days.
MEI Pharma’sloss per share estimates have narrowed from 58 cents to 14 cents for 2020 and from 53 cents to 39 centsfor 2021 over the past 60 days.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>